NCT05576389RecruitingPhase 2
Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study
Peking University People's Hospital1 site in 1 country64 target enrollmentStarted: October 1, 2022Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 64
- Locations
- 1
- Primary Endpoint
- tpCR（ypT0/is ypN0）
Study Overview
Brief Summary
This study is an open-label, single-arm, multicenter clinical study. 64 patients with germline BRCA-mutated HER2-negative early breast cancer are planned to be enrolled and treated with fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of neoadjuvant fluzoparib combined with camrelizumab in the treatment of germline BRCA-mutated HER2-negative early breast cancer。
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •According to the definition of the latest ASCO/CAP guidelines, early or locally advanced HER2 negative invasive breast cancer confirmed by histopathology meets the following conditions:
- •HER2 negative: IHC 0/1+or IHC2+with no amplification of ISH;
- •Primary tumor size: ≥ 1cm
- •Lymph node status: N0-3
- •Inflammatory breast cancer patients with measurable lesions (according to RECIST 1.1 standard)
- •Patients with bilateral breast cancer whose primary lesions all meet the inclusion criteria, or breast cancer with Tis-1bN0 and HER2 negative on the other side only meeting the inclusion criteria on one side;
- •The hormone receptor status is known;
- •ECOG score 0-1;
- •Carrying BRCA1 or BRCA2 germline pathogenic mutations or suspected pathogenic mutations;
- •According to RECIST 1.1 standard, at least one measurable lesion is present;
Exclusion Criteria
- •Tumor related symptoms and treatment
- •Recurrent or metastatic breast cancer;
- •Participated in other drug trials or received any anti-tumor therapy, including endocrine therapy, bisphosphate therapy, immunotherapy, biological therapy, or tumor embolization, within 4 weeks prior to enrollment;
- •Previously received treatment for PD-1/PD-L1 antibodies, CTLA-4 antibodies, or other PD-1/PD-L1 inhibitors;
- •Previously received PARP inhibitor treatment (excluding those who have completed PARP inhibitor treatment for ovarian cancer for at least 5 years without recurrence or metastasis);
- •Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); active hepatitis or combined hepatitis B and C co-infection; autoimmune hepatitis;
- •Confirmed history of heart failure or systolic dysfunction (LVEF < 50%); high risk uncontrolled cardiac arrhythmias, such as atrial tachycardia; angina requiring antianginal medication
- •Female patients who are pregnant or lactating
- •History of definite neurological or psychiatric disorders, including epilepsy or dementia
- •Presence of interstitial lung disease, pneumonitis, or uncontrolled systemic disease (eg, diabetes mellitus, pulmonary fibrosis, acute pneumonitis, etc.)
Arms & Interventions
Camrelizumab+Fluzoparib
Experimental
Fluzoparib combined with Carolizumab for 8 cycles of neoadjuvant therapy. Allowing the continued use of combination therapy or monotherapy with Carolizumab and fluzoparib during the adjuvant therapy phase, with an overall treatment duration not exceeding 12 months.
Intervention: Camrelizumab+Fluzoparib (Drug)
Outcomes
Primary Outcomes
tpCR（ypT0/is ypN0）
Time Frame: 6 months
total pathological complete response
Secondary Outcomes
No secondary outcomes reported
Investigators
Shu Wang
Chief Physician
Peking University People's Hospital
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene MutationHer-2 Negative Breast CancerHRR Gene MutationNCT05761470Ying Lin66
Recruiting
Phase 3
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT05042375Jiangsu HengRui Medicine Co., Ltd.450
Not yet recruiting
Phase 2
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryHigh Grade Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian-tube CancerOvarian CancerNCT06063070Sun Yat-sen University44
Unknown
Phase 3
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)PD-L1 Positive Non-small Cell Lung CancerNCT04203485Jiangsu HengRui Medicine Co., Ltd.762
Unknown
Phase 2
Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCCHead and Neck Squamous Cell CarcinomaNCT04399785Xingchen Peng34